Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 2.6%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded down 2.6% during mid-day trading on Tuesday . The stock traded as low as $7.17 and last traded at $7.21. 1,887,338 shares changed hands during trading, a decline of 69% from the average session volume of 6,175,219 shares. The stock had previously closed at $7.40.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. KeyCorp cut their target price on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday. Needham & Company LLC reissued a “buy” rating and set a $17.00 target price on shares of Recursion Pharmaceuticals in a research note on Tuesday, June 25th.

Recursion Pharmaceuticals Price Performance

The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of -4.80 and a beta of 0.83. The business’s fifty day moving average price is $8.74 and its 200-day moving average price is $9.81.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.04. The firm had revenue of $13.80 million during the quarter, compared to analysts’ expectations of $11.10 million. Recursion Pharmaceuticals had a negative net margin of 765.90% and a negative return on equity of 79.96%. The business’s revenue was up 14.0% on a year-over-year basis. During the same period last year, the company earned ($0.34) earnings per share. Equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Christopher Gibson sold 50,000 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $7.73, for a total transaction of $386,500.00. Following the completion of the transaction, the chief executive officer now directly owns 863,524 shares in the company, valued at $6,675,040.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, COO Tina Marriott sold 3,000 shares of the business’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $8.78, for a total transaction of $26,340.00. Following the transaction, the chief operating officer now directly owns 535,457 shares in the company, valued at $4,701,312.46. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Christopher Gibson sold 50,000 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $7.73, for a total transaction of $386,500.00. Following the transaction, the chief executive officer now owns 863,524 shares in the company, valued at $6,675,040.52. The disclosure for this sale can be found here. Insiders sold 233,806 shares of company stock worth $1,898,027 over the last three months. 15.75% of the stock is currently owned by insiders.

Institutional Trading of Recursion Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in RXRX. Benjamin F. Edwards & Company Inc. bought a new stake in Recursion Pharmaceuticals in the first quarter worth about $26,000. National Bank of Canada FI raised its position in Recursion Pharmaceuticals by 90.9% in the fourth quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock worth $31,000 after acquiring an additional 1,500 shares during the period. First Horizon Advisors Inc. bought a new stake in Recursion Pharmaceuticals in the fourth quarter worth about $47,000. GAMMA Investing LLC raised its position in Recursion Pharmaceuticals by 1,588.4% in the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after acquiring an additional 6,036 shares during the period. Finally, Oxford Wealth Group LLC bought a new stake in Recursion Pharmaceuticals in the first quarter worth about $106,000. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.